This is the United States Government patent on the medicinal values of this plant.  But, NO medical benefit??  Read this one if nothing else.

US6630507  Autoimmune Disorders; Cannabiniods as antioxidants & neuroprotectants

Cited Patent Filing date Publication date Applicant Title
​
US2304669  Aug 16, 1940 Dec 8, 1942 Adams Roger Isolation of cannabidiol

US6410588B1 1998-04-14 2002-06-25 anti-inflammatory agents ​The Mathilda And Terence Kennedy Institute Of Rheumatology   Use of cannabinoids as anti-inflammatory agents 
US20070099987A1  Treating or preventing diabetes with cannabidiol
​US6630507  Autoimmune Disorders; Cannabiniods as antioxidants & neuroprotectants
1989 -  Antiinflammatory and antimicrobial compounds and compositions
United States Patent 4837228.

US4876276  Oct 26, 1987 Oct 24, 1989 Yissum Research Development Co. Of The Hebrew University Of Jerusalem(3S-4S)-7-                                hydroxy-Δ6 -tetrahydrocannabinols
US5227537  Jan 8, 1992Jul 13, 1993 Heinrich Mack Nachf. Method for the production of 6,12-dihydro-6-hydroxy-cannabidiol and                          the use thereof for the production of trans-delta-9-tetrahydrocannabinol
US5284867  Apr 8, 1992Feb 8, 1994 Yissum Research Development Company Of The Hebrew University In Jerusalem NMDA-                              blocking pharmaceutical compositions
US5434295  Feb 7, 1994Jul 18, 1995Yissum Research Development Company Neuroprotective pharmaceutical compositions of                         4-phenylpinene derivatives and certain novel 4-phenylpinene compounds
US5462946  Mar 20, 1992Oct 31, 1995The United States Of America As Represented By The Department Of Health And Human                          Services Nitroxides as protectors against oxidative stress
US5512270  Aug 31, 1994Apr 30, 1996Duke University Method of inhibiting oxidants using alkylaryl polyether alcohol polymers
US5521215  Feb 7, 1994May 28, 1996Ramot University Authority For Applied Research And Industrial Development Ltd. NMDA-                          blocking pharmaceuticals
US5538993  Feb 7, 1994Jul 23, 1996Yissum Research Development Company Certain tetrahydrocannabinol-7-oic acid                                          derivatives
US5635530  Sep 11, 1992Jun 3, 1997Yissum Research Development Company Of The Hebrew University Of Jerusalem(3S,4S)                            -delta-6-tetrahydrocannabinol-7-oic acids and derivatives thereof, processors for their preparation and                                                pharmaceutical compositions containing them
US5696109  Jun 7, 1995Dec 9, 1997Eukarion, Inc. Synthetic catalytic free radical scavengers useful as antioxidants for                                          prevention and therapy of disease
US6410588  Apr 14, 1999Jun 25, 2002The Mathilda And Terence Kennedy Institute Of RheumatologyUse of cannabinoids as                              anti-inflammatory agents
EP0427518A1  Nov 6, 1990May 15, 1991Yissum Research Development Company Of The Hebrew University Of Jerusalem                                       NMDA-Blocking compounds, pharmaceutical compositions, their preparation and use
EP0576357A1  Jun 23, 1993Dec 29, 1993SanofiPyrazole derivatives, process for their preparation and pharmaceutical                                                compositions containing them
EP0656354A1  Nov 29, 1994Jun 7, 1995SanofiSubstituted N-piperidino 3-pyrazolecarboxamide
EP0658546A1   Dec 15, 1994Jun 21, 1995SanofiNovel 3-pyrazolecarboxamide derivatives with cannabinoid receptor affinity
WO1993005031A1   Sep 11, 1992Mar 18, 1993Yissum Research Development Company Of The Hebrew University In Jerusalem                                       ( 3s,4s)-delta-6-tetrahydrocannabinol-7-oic acids and derivatives thereof, processes for their preparation                                            and pharmaceutical compositions containing them
WO1994012667A1   Nov 29, 1993Jun 9, 1994The United States Department Of The ArmyInhibitors of arachidonic acid                                                        metabolites for preventing neurological damage
WO1996012485A1   Oct 18, 1995May 2, 1996Eli Lilly And Company Treatment of disorders with duloxetine
WO1996018600A1   Dec 13, 1995Jun 20, 1996Lifegroup S.P.A. Amides of mono and bicarboxylic acids with amino acids or                                                glycosamines, selectively active on the cannabinoid peripheral receptor
WO1997019063A1  Nov 21, 1996May 29, 1997SanofiPyrazole derivatives, method for preparing same, and pharmaceutical                                               compositions containing said derivatives
WO1999053917A1 *Apr 21, 1999Oct 28, 1999The Government Of The United States Of America, Represented By The Secretary,                                       Department Of Health And Human Services Cannabinoids as antioxidants and neuroprotectants